NeoGenomics Inc. Common Stock vs Revvity Inc — how do they compare? NeoGenomics Inc. Common Stock trades at $16.85 (market cap $2.14B), while Revvity Inc trades at $151.84 (market cap $17.30B). The key difference: Revvity Inc is far larger — about 8.1× NeoGenomics Inc. Common Stock's market cap, and Revvity Inc pays a 0.18% dividend while NeoGenomics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold NeoGenomics Inc. Common Stock for 0 Days and Revvity Inc for 13 Days on average.
| NEO | RVTY | |
|---|---|---|
Market Cap | $2.14B | $17.30B |
Volume | 2,228,400 | 1,387,588 |
Sector | Health | Health |
52-Week High | $19.91 | $157.36 |
52-Week Low | $7.19 | $82.26 |
Typical Hold Time | 0 Days | 13 Days |
Enterprise Value | $2.44B | $19.62B |
Dividend Yield | — | 0.18% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
RVTY trades at $155.08, down 0.34% on the day but near its 52-week high of $158.28. The stock shows strong technical momentum with bullish moving averages and has consistently beaten earnings estimates in recent quarters. Recent developments include the launch of a new diabetes detection kit in Europe and the acquisition of Human Cell Design to expand metabolic disease research capabilities. The company maintains solid profitability with 54.98% gross margins and positive cash flow trends.
RVTY presents growth potential through diagnostic expansion and AI-driven demand, though premium valuation metrics (P/E 74.56) require careful consideration. Near-term catalysts include Q3 earnings on November 3, 2026, while risks involve China market pressures and margin compression. Analyst consensus leans bullish with 52% buy ratings and a $132.13 price target, suggesting potential downside from current levels despite positive momentum.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
NeoGenomics, Inc. is a US cancer diagnostics company that provides genomic and pathology testing services, offering an oncology-focused testing menu used by oncologists, pathologists, and hospital systems across the cancer care continuum.
Read more on NEO →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →